Health Care [ 6/12 ] | Biotechnology [ 31/73 ]
NASDAQ | Common Stock
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain.
Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression.
The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital.
NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 25 | -0.34 Increased by +54.05% | -0.53 Increased by +35.85% |
| Mar 26, 25 | -0.77 Decreased by -54.00% | -0.37 Decreased by -108.11% |
| Nov 11, 24 | -0.15 Decreased by -114.29% | -0.64 Increased by +76.56% |
| Aug 14, 24 | -0.67 Decreased by -458.33% | -0.69 Increased by +2.90% |
| May 14, 24 | -0.74 Decreased by -362.50% | -0.55 Decreased by -34.55% |
| Mar 29, 24 | -0.50 Decreased by -212.50% | -0.70 Increased by +28.57% |
| Nov 13, 23 | -0.07 Increased by +50.00% | -0.11 Increased by +36.36% |
| Aug 14, 23 | -0.12 Decreased by -9.09% | -0.14 Increased by +14.29% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 4.00 K Decreased by -50.00% | -5.51 M Increased by +15.56% | Decreased by -137.80 K% Decreased by -68.87% |
| Dec 31, 24 | 4.00 K Decreased by -50.00% | -9.08 M Decreased by -109.56% | Decreased by -226.95 K% Decreased by -319.11% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -1.62 M Increased by +73.23% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -7.90 M Increased by +9.41% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 8.00 K Increased by +N/A% | -6.53 M Increased by +40.86% | Decreased by -81.60 K% Decreased by N/A% |
| Dec 31, 23 | 8.00 K Increased by +N/A% | -4.33 M Increased by +57.70% | Decreased by -54.15 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -6.06 M Increased by +33.26% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -8.72 M Decreased by -24.85% | Decreased by N/A% Decreased by N/A% |